BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 36828346)

  • 1. The adaptor protein VEPH1 interacts with the kinase domain of ERBB2 and impacts EGF signaling in ovarian cancer cells.
    Kollara A; Burt BD; Ringuette MJ; Brown TJ
    Cell Signal; 2023 Jun; 106():110634. PubMed ID: 36828346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased androgen receptor levels and signaling in ovarian cancer cells by VEPH1 associated with suppression of SMAD3 and AKT activation.
    Kollara A; Shathasivam P; Park S; Ringuette MJ; Brown TJ
    J Steroid Biochem Mol Biol; 2020 Feb; 196():105498. PubMed ID: 31614206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VEPH1 expression decreases vascularisation in ovarian cancer xenografts and inhibits VEGFA and IL8 expression through inhibition of AKT activation.
    Shathasivam P; Kollara A; Spybey T; Park S; Clarke B; Ringuette MJ; Brown TJ
    Br J Cancer; 2017 Apr; 116(8):1065-1076. PubMed ID: 28301874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VRK2 inhibits mitogen-activated protein kinase signaling and inversely correlates with ErbB2 in human breast cancer.
    Fernández IF; Blanco S; Lozano J; Lazo PA
    Mol Cell Biol; 2010 Oct; 30(19):4687-97. PubMed ID: 20679487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA miR-23b-3p promotes osteosarcoma by targeting ventricular zone expressed PH domain-containing 1 (VEPH1)/phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) pathway.
    Fan L; Cao X; Lei Y
    Bioengineered; 2021 Dec; 12(2):12568-12582. PubMed ID: 34903122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells.
    Brockhoff G; Heiss P; Schlegel J; Hofstaedter F; Knuechel R
    Cytometry; 2001 Aug; 44(4):338-48. PubMed ID: 11500850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human ortholog of Drosophila Melted impedes SMAD2 release from TGF-β receptor I to inhibit TGF-β signaling.
    Shathasivam P; Kollara A; Ringuette MJ; Virtanen C; Wrana JL; Brown TJ
    Proc Natl Acad Sci U S A; 2015 Jun; 112(23):E3000-9. PubMed ID: 26039994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ventricular Zone Expressed PH Domain Containing 1 (VEPH1): an adaptor protein capable of modulating multiple signaling transduction pathways during normal and pathological development.
    Brown TJ; Kollara A; Shathasivam P; Ringuette MJ
    Cell Commun Signal; 2019 Sep; 17(1):116. PubMed ID: 31500637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects.
    Jackson JG; St Clair P; Sliwkowski MX; Brattain MG
    Cancer Res; 2004 Apr; 64(7):2601-9. PubMed ID: 15059917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A differential requirement for the COOH-terminal region of the epidermal growth factor (EGF) receptor in amphiregulin and EGF mitogenic signaling.
    Wong L; Deb TB; Thompson SA; Wells A; Johnson GR
    J Biol Chem; 1999 Mar; 274(13):8900-9. PubMed ID: 10085134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LASP-1 interacts with ErbB2 in ovarian cancer cells.
    Sidhanth C; Bindhya S; Shabna A; Krishnapriya S; Manasa P; Nagare RP; Joshua T; Sneha S; Murhekar K; Ganesan TS
    Biochem J; 2022 Jan; 479(1):23-38. PubMed ID: 34881777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer.
    Nakayama N; Nakayama K; Yeasmin S; Ishibashi M; Katagiri A; Iida K; Fukumoto M; Miyazaki K
    Br J Cancer; 2008 Dec; 99(12):2020-8. PubMed ID: 19018267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor-stimulated Akt phosphorylation requires clathrin or ErbB2 but not receptor endocytosis.
    Garay C; Judge G; Lucarelli S; Bautista S; Pandey R; Singh T; Antonescu CN
    Mol Biol Cell; 2015 Oct; 26(19):3504-19. PubMed ID: 26246598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gab1 is required for EGF receptor signaling and the transformation by activated ErbB2.
    Yamasaki S; Nishida K; Yoshida Y; Itoh M; Hibi M; Hirano T
    Oncogene; 2003 Mar; 22(10):1546-56. PubMed ID: 12629518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways.
    Xia W; Mullin RJ; Keith BR; Liu LH; Ma H; Rusnak DW; Owens G; Alligood KJ; Spector NL
    Oncogene; 2002 Sep; 21(41):6255-63. PubMed ID: 12214266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor (EGF) receptor kinase-independent signaling by EGF.
    Deb TB; Su L; Wong L; Bonvini E; Wells A; David M; Johnson GR
    J Biol Chem; 2001 May; 276(18):15554-60. PubMed ID: 11279155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Egr-1 mediates epidermal growth factor-induced downregulation of E-cadherin expression via Slug in human ovarian cancer cells.
    Cheng JC; Chang HM; Leung PC
    Oncogene; 2013 Feb; 32(8):1041-9. PubMed ID: 22508482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of ErbB2 in the signaling pathway leading to cell cycle progression from a truncated epidermal growth factor receptor lacking the C-terminal autophosphorylation sites.
    Sasaoka T; Langlois WJ; Bai F; Rose DW; Leitner JW; Decker SJ; Saltiel A; Gill GN; Kobayashi M; Draznin B; Olefsky JM
    J Biol Chem; 1996 Apr; 271(14):8338-44. PubMed ID: 8626530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dampened VEPH1 activates mTORC1 signaling by weakening the TSC1/TSC2 association in hepatocellular carcinoma.
    Dong P; Wang X; Liu L; Tang W; Ma L; Zeng W; Sun S; Zhang L; Zhang N; Shen X; Janssen HLA; Dong L; Zhang S; Chen S
    J Hepatol; 2020 Dec; 73(6):1446-1459. PubMed ID: 32610114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGF promotes neuroendocrine-like differentiation of prostate cancer cells in the presence of LY294002 through increased ErbB2 expression independent of the phosphatidylinositol 3-kinase-AKT pathway.
    Cortés MA; Cariaga-Martinez AE; Lobo MV; Martín Orozco RM; Motiño O; Rodríguez-Ubreva FJ; Angulo J; López-Ruiz P; Colás B
    Carcinogenesis; 2012 Jun; 33(6):1169-77. PubMed ID: 22461520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.